Business Description
![Titan Pharmaceuticals Inc Titan Pharmaceuticals Inc logo](https://static.gurufocus.com/logos/0C00000CNT.png?14)
Titan Pharmaceuticals Inc
NAICS : 325414
SIC : 2836
ISIN : US8883143096
Description
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 186.64 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -79.07 | |||||
Beneish M-Score | 881.24 | |||||
WACC vs ROIC |
Growth Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -92.9 | |||||
3-Year EBITDA Growth Rate | 36.6 | |||||
3-Year EPS without NRI Growth Rate | 34 | |||||
3-Year FCF Growth Rate | 53.5 | |||||
3-Year Book Growth Rate | -4.9 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
9-Day RSI | 43.73 | |||||
14-Day RSI | 47.69 | |||||
6-1 Month Momentum % | 0.63 | |||||
12-1 Month Momentum % | -60.55 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 11.83 | |||||
Quick Ratio | 11.83 | |||||
Cash Ratio | 11.02 | |||||
Days Sales Outstanding | 16279 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -29.8 | |||||
Shareholder Yield % | -2.75 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -664300 | |||||
Net Margin % | -495400 | |||||
FCF Margin % | -536900 | |||||
ROE % | -126.92 | |||||
ROA % | -89.39 | |||||
ROIC % | -1051.44 | |||||
ROC (Joel Greenblatt) % | -4950.07 | |||||
ROCE % | -169.91 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 5150 | |||||
PB Ratio | 0.77 | |||||
Price-to-Tangible-Book | 0.77 | |||||
EV-to-EBIT | 0.21 | |||||
EV-to-EBITDA | 0.22 | |||||
EV-to-Revenue | -1417 | |||||
EV-to-Forward-Revenue | 68.41 | |||||
EV-to-FCF | 0.24 | |||||
Price-to-Net-Current-Asset-Value | 0.78 | |||||
Price-to-Net-Cash | 0.84 | |||||
Earnings Yield (Greenblatt) % | 476.19 | |||||
FCF Yield % | -123.32 |